Nanoscience and Nanotechnology Research, 2017, Vol. 4, No.

2, 67-72
Available online at [Link]
©Science and Education Publishing
DOI:10.12691/nnr-4-2-5

Solid Lipid Nanoparticles: A Review

Vishal J. Lingayat*, Nilesh S. Zarekar, Rajan S. Shendge

Department of Pharmaceutics (PG), Sanjivani College of Pharmaceutical Education and Research, Kopargaon
*Corresponding author: vishallingayat397@[Link]

Abstract Solid lipid nanoparticles are at the forefront of the rapidly developing field of nanotechnology with
several potential applications in drug delivery, clinical medicine, and research, as well as in other varied sciences.
This review presents a broad treatment of solid lipid nanoparticles discussing their aims, production procedures,
advantages, limitations and their possible remedies. This review presents a broad treatment of solid lipid
nanoparticles discussing preparation method, characterization, route of administration of SLNs, generally carried out.
Aspects of SLN route of administration and the invivo fate of the carriers are also discussed.

Keywords: solid lipid nanoparticles, methods of preparation, evaluation, route of administration

Cite This Article: Vishal J. Lingayat, Nilesh S. Zarekar, and Rajan S. Shendge, “Solid Lipid Nanoparticles:
A Review.” Nanoscience and Nanotechnology Research, vol. 4, no. 2 (2017): 67-72. doi: 10.12691/nnr-4-2-5.

1. Introduction
Solid lipid nanoparticles (SLNs) are introduced as a
carrier system for in effectively water dissolvable
medication and corrective dynamic medication. Colloidal
particles ranging in size between 10 and 1000 nm are
known as nanoparticles. They are incorporated from
manufactured characteristic polymers and suited to
advance medication conveyance and lessen lethality [1].
They have developed as a variable substitute to liposomes
as medication carrier. They are fabricated from
manufactured/characteristic polymers and preferably
suited to improve sedate conveyance and diminish
lethality [2]. SLN offer interesting properties, for example,
little size, huge surface zone, high medication stacking
and the communication of stages at the interface and are
appealing for their potential to enhance execution of
pharmaceuticals [3]. Solide lipid nanoparticles (SLN)
Figure 1. Structure of Solid Lipid Nanoparticle (Sln) [5]
are aqueous colloidal dispersions, the matrix of
which comprises of Solide biodegradable lipids. SLNs They have many focal points, for example, great
consolidate the favorable circumstances and maintain a biocompatibility, low danger and lipophilic medications
strategic distance from the down sides of a few colloidal are better conveyed by Solide lipid nanoparticles and the
carriers of its class, for example, physical stability, framework is physically stable.
assurance of fused labile medications from protection, of
incorporated labile drugs from degradation, controlled 1.1. Advantages of SLN [3,6,7]
release, excellent tolerability SLN formulations for
various application routes (parenteral, oral, dermal, visual, • Small estimate and generally contract measure
pulmonar, rectal) have been developed and thoroughly dissemination which gives natural chances to site-
characterized in-vitro and in-vivo[4]. particular medication conveyance by SLNs [8].
Solid lipid nanoparticles are one of the novel potential • Conventional emulsion producing techniques
colloidal transporter system as option materials to pertinent
polymers which is in distinguishable to oil in water • Can be stop dried to shape powdered detailing
emulsion for parenteral nourishment, however the fluid • Controlled arrival of dynamic medication over a
lipid of the emulsion has been supplanted by a Solide lipid long stretch can be achieved [8].
nanopartical on Figure 1. • Excellent biocompatibility [9].
 Nanoscience and Nanotechnology Research 68

• Improve stability of pharmaceuticals [10]. be infused, grouping of lipid, temperature, mixing, sort of
• Excellent reproducibility with a savvy high-weight natural dissolvable and emulsifier [27]. SLNs are set up
homogenization technique as the readiness from lipid, emulsifier and water/dissolvable by utilizing
methodology. diverse techniques and are enroll beneath.
• High and enhanced drug content.
• The achievability of consolidating both hydrophilic 3.1. High weight homogenization [28,29]
and hydrophobicmedications.
• The transporter lipids are biodegradable and 3.1.1. Hot homogenization.
consequently protected. Avoidance of natural 3.1.2. Cold homogenization.
solvents. Enhanced bioavailability of inadequately
water dissolvable atoms [11]. 3.2. Ultrasonication/fast Homogenization
• Avoidance of natural solvents underway strategies
[12]. 3.2.1. Test Ultrasonication.
3.1.2.. Shower Ultrasonication.
• Feasible huge scale generation and cleansing.

1.2. Disadvantages of SLN [3,11,13]. 3.3. Solvent evaporation method.

• Poor sedate stacking limit. 3.4. Solvent emulsification-diffusion method.

• Drug ejection after polymeric move amid capacity.
• Unpredictable gelation propensity. 3.5. Supercritical fluid method.
• The low ability to stack hydrophilic medications
because of apportioning impacts amid the
generation procedure [14].
3.6. Microemulsion based method.

3.7. Spray drying method.

2. Aims of SLN’s [15-21].
3.8. Double emulsion method.
• Possibility of controlled medication discharge and
medication focusing on 3.9. Precipitation technique.
• More moderate (less costly than polymeric/surfactant
based transporters).
• Incorporation of lipophilic and hydrophilic medications 3.10. Film-ultrasound dispersion.
attainable
• Avoidance of natural solvents. 4. Characterization of Solid Lipid
• Problems concerning substantial scale generation
and sanitization Nanoparticles (SLNs)
• Increased sedate security.
• No biotoxicity of the transporter in light of the fact Characterization of Solide lipid nanoparticles is a
that, most lipids are biodegradable genuine test because of the little size of the particles
• Increased Bioavailability of ensnared bioactive mixes andcomplexity of the framework. The essential parameters
which should be assessed for the SLNs are, Partical
estimate, measure conveyance energy (zeta potential),
3. Methods of Preparation of Solid Lipid level of crystallinity and lipid alteration (polymorphism),
conjunction of extra colloidal structures (micelles,
Nanoparticles [2,7,11,21,22,23,24] liposome, super cooled, softens, sedate nanoparticles),
time size of circulation procedures, tranquilize , in vitro
Strategy for readiness of SLN incorporates high shear medicate discharge and surface morphology [30].Several
homogenization, ultrasonication, microemulsion based parameters which must be considered in Characterization
SLN planning, supercritical liquid innovation, splash are as per the following
drying, dissolvable emulsification/vanishing, dissolvable
infusion method and dissolvable emulsification-dissemination 4.1. Partical Size and Zeta Potential
[25].
As of late, this method has likewise utilized to plan Size of nanoparticles can be dictated by a few
lipid nanoparticles [26]. This procedure depends on the techniques, for example, photon-connection spectrometry
precipitation of lipid broke down in arrangement. In this (PCS), transmission electron microscopy (TEM), and
strategy dissolvable removal happens and lipid accelerate checking electron microscopy (SEM), SEM joined with
in a similar time. Dissolvable expulsion is fundamental vitality dispersive X-Beam spectrometry, filtered test
and can be performed by refining or other technique if microscopy and fraunhofer diffraction. Among these, the
don't evacuate under given condition. The lipid most broadly utilized procedures are PCS and electron
nanoparticles arrangement happens after vanishing of the microscopy techniques. SEM and TEM are exceptionally
water immiscible natural dissolvable. Partical size is relies helpful fit as a fiddle and morphology of lipid
on upon the different parameters, for example, add up to nanoparticles and furthermore permit assurance of Partical
69 Nanoscience and Nanotechnology Research

size and dissemination. Another progressed tiny strategy circumstances, centrifuged and measured for medication .
utilized for Characterization of nanoparticles is nuclear Impose and Benita (1990) have revealed another system
drive microscopy (AFM) [31]. This is another instrument which keeps away from the fenced in area of the colloidal
to picture the first unaltered shape and surface properties medication bearer in a dialysis sac and depends on switch
of the particles. In this system, the drive acting between dialysis. This technique is not sufficiently touchy to
the surface and examining tip brings about a spatial describe fast discharge rate of medication from colloidal
determination up to 0.01μm. Laser diffraction procedure transporter [37].
could likewise be utilized which is appropriate for sub
micrometer run particles and figurings depend on the 4.4. Storage Stability
refractive list of the scattering medium water (1.33) and
on the lipid particles [32]. The Partical estimate relies on The physical solidness of the SLNs amid delayed
upon the lattice constituents and also on the sort and stockpiling can be controlled by checking changes in
measure of emulsifying specialists and lipids. It has been Partical estimate, tranquilize substance, appearance and
accounted for that expansion in measure of emulsifier Viscosity. This should likewise be possible by thin layer
declines the mean width of the mass [31]. The size and chromatography [38,39].
structure of joined medication additionally influences Outer parameters, for example, temperature and light
normal distance across of the SLNs [33]. Photon give off an impression of being of essential significance
connection spectroscopy (PCS) is otherwise called for long - term steadiness. The zeta potential ought to be
dynamic light diffusing. This strategy measures the as a rule, stay higher than - 60mV for a scattering to
variance of the power of the scattered light which is remain physically steady.
created by Partical development and gives a size range 4°C - Most positive stockpiling temperature.
from 3 nanometres to 3 microns [34,35]. 20°C- Long term storage did not bring about
medication stacked SLN total or loss of medication.
4.2. Determination of Incorporated Drugs 50°C - A fast development of Partical size was watched
[40].
The measure of medication fused is resolved after partition
of the free medication and Solide lipids from the fluid 4.5. Crystallization Tendency and
medium and the detachment completed by ultracentrifugation,
centrifugation filtration or gel penetration chromatography.
Polymorphic Behaviour of SLNs
Tranquilize substance can likewise be resolved specifically Uncommon thought must be given to crystallization of
by removing the medication with appropriate dissolvable lipids since this is related with medication fuse and
under ideal conditions and afterward investigation of came discharge rates. The Solide condition of the particles is of
about item in SLNs. real significance, as it diminishes the portability of
Models have been proposed to portray the limitation of joined medications and in this manner keeping drug
medication atoms in SLNs [36]. The improved shell spillage from the bearer. Fundamental procedures to set up
model is described by medication specifically situating at the physic-substance condition of particles incorporate
the interface, either by quick hardening of the network warm investigation and X-beam diffraction [41,42]. In
lipid or by effective rivalry of the medication for the warm investigation most generally utilized strategies are
interface. Sedate scattered by such a model may show a differential warm examination (DTA) and differential
fruitful burst impact amid medication discharge. The filtering Calorimetry (DSC).
homogeneous framework model is portrayed by
medication scattered equitably all through the lattice,
much like a Solide arrangement. The advanced center 5. Evaluation of Solid Lipid Nanoparticles
model is described by medication selectivity situated at
the center of the Solide lipid nanoparticles, maybe because
[25,43]
of more quick hardening of the medication in respect to
the grid material. The advanced center model would be 5.1. Electron Microscopy of Solid Lipid
helpful to create a film controlled discharge design. In Nanoparticles
spite of the fact that the compound solidness and the
discharge energy of medications are to a great extent Solide lipid nanoparticles were seen by transmission
identified with restriction of medications inside the totals, electron microscopy. Tests of SLN were weakened to ten
more research is still required to approve these models. time and after that mounted on gold plate. The mounted
plates were dried and inspected under a transmission
electron magnifying instrument without utilizing any sort
4.3. In-vitro Drug Release Studies of stain. The CCD camera and delicate picture framework
In-vitro tranquilize discharge studies are for the most was utilized with the transmission electron magnifying
part helpful for quality control and also for the expectation instrument to envision SLN [44].
of in-vivo energy. Discharge profile of medication can be
led in dialysis tubing or without tubing. In dialysis, the 5.2. Zeta potential of Solide Lipid
SLNs scattering is brought into prewashed dialysis tubing, Nanoparticles
which is then hermetically fixed and after that dialyzed
against disintegration medium at consistent temperature Zeta potential of SLN definitions were dictated by
with steady mixing. Tests were taken at various Zetasizer). Tests were fittingly weakened with deionized
 Nanoscience and Nanotechnology Research 70

water to get 50 and 200 Kcps for the estimations. Tests 6. Route of Administration
were put in the cubit accessible for instrument and zeta
potential measured specifically [45,46]. SLNs are given by taking after course of organization

5.3. Particle Size and Polydispersity Index of 6.1. Oral Organization

Solid Lipid Nanoparticles
Oral organization of SLN is conceivable as watery
The normal Partical size and polydispersity file of SLN scattering or on the other hand after change into a
details were measured by Zetasizer DTS (Malvern conventional measurement shape, i.e. tablets, pellets,
Instrument, UK). The specimens of SLN scatterings were containers or powders in sachets [50]. For the generation
weakened with deionized water [45]. The aftereffects of of tablets the fluid SLN scattering can be utilized rather
normal Partical size and polydispersity record were gotten than a granulation Fuid in the granulation process [51].
from instrumental based computation system [29]. Types of SLNs planning which are given by oral course
are fluid scatterings. SLNs stacked dose shape, for
5.4. Encapsulation Efficiency of Solid Lipid example, tablets, pellets and case. The microclimate of the
Nanoparticles stomach favors Partical conglomeration because of the
causticity and high ionic quality. It is not out of the
Measure of testosterone epitomized in Solide lipid ordinary that nourishment will largy affect SLN execution
nanoparticles were figured as typified productivity (EE). [52].
Solide lipid nanoparticles were kept in dialysis tube and
dialyzed. Thirty milliliter of 30% v/v PEG 400 in 6.2. Parenteral Organization
phosphate cushion (pH-6) arrangement was utilized as
dialyzing medium [47]. Dialysis of Solide lipid SLNs for the most part directed intravenously to
nanoparticles was performed for two hour. The one creatures. Conveyance of SLN were found to have higher
hundred miligram of dialyzed Solide lipid nanoparticles medication fixations in lung, spleen and cerebrum, while
were taken from dialysis pack and broke down for the arrangement prompted to more dissemination into
medication content by elite fluid chromatography (HPLC), liver and kidneys [53]. SLN demonstrated higher blood
(Shimadzu, Japan) at 254 nm. The examples were levels in contrast with a business sedate arrangement after
appropriately weakened and separated through Millipore intravenous. For parenteral organization, SLN scatterings
film channel (0.2 μm). must be sterile. The mean particle so sterile filtration is un
realistic in these cases. [50]
5.5. Viscosity of Solide Lipid Nanoparticles
6.3. Transdermal Application
Viscosity of testosterone containing Solide lipid
nanoparticles was measured by Brookfield viscometer The littlest Partical sizes are watched for SLN
(DV-E viscometer, Brookfield, USA) utilizing shaft no 63 scatterings with low lipid content (up to 5%). Drawbacks
at 30 r/m in surrounding condition. The shaft speed no 63 of dermal organization are low grouping of the scattered
was settled in viscometer nobe and most extreme torque lipid and the low thickness. The joining of the SLN
was measured before watching Viscosity. Viscosity of scattering in a treatment or gel is important so as to
testosterone containing Solide lipid nanoparticles was accomplish a plan which can be regulated to the skin [54].
measured specifically from the viscometer computerized
show [48].
6.4. Pulmonary Administration
5.6. In Vitro Release Study of Solid Lipid An extremely fascinating application has all the
Nanoparticles earmarks of being the aspiratory organization of SLN.
SLN powders can't be regulated to the lung in light of the
The in vitro sedate discharge concentrate Solide lipid fact that the Partical size is too little and they will be
nanoparticles was performed by privately created Franz breathed out. An exceptionally straightforward approach
dispersion sort cell. The review was performed at 30±2°C is the aerosolization of fluid SLN scatterings [21]. The
temperature. Receptor compartment of dissemination cell critical point is that the SLN ought not total amid the
contained 30 ml 30% v/v PEG 400 in phosphate cradle aerosolization. The vaporized beads were gathered by
(pH-6) arrangement and was always mixed by an impact of airborne with a glass mass of a measuring glass.
attractive stirrer at 50 r/m. Dialysis layer (sub-atomic This essentially exhibits SLN are appropriate for lung
weight cut off 12 KD was utilized as discharge hindrance conveyance. After restriction into the bronchial tube and
in the middle of receptor and benefactor compartment in the alveoli, the medication can be discharged
which was beforehand was with refined water and doused controlledly from the lipid particles [55].
with 30% v/v PEG 400 arrangement. Time to time 5 ml
tests was pulled back through the examining port of the 6.5. Rectal Organization
dissemination cell in interims one h, more than 8 h. Same
measure of 30% v/v PEG 400 arrangement was supplanted Customary rectal conveyance of medications is as often
instantly. The gathered examples were reasonably as possible utilized for pediatric patients because of simple
weakened and examined by HPLC at 254 nm [49]. application. At the point when expedient pharmacological
71 Nanoscience and Nanotechnology Research

impact is required, in a few conditions, parenteral or rectal [20] Muller, R., Schwarz, C., Mehnertw, and Lucks, J, “Production Of
organization is favored. The plasma levels and helpful Solid Lipid Nanoparticles For Controlled Drug Delivery”, Int.
Symp Control Release Bioact. Mater, 1., 480-481. 1993.
adequacy of rectally directed medications were accounted [21] Yadav, N., Khatak, S. And Singh, S., “Solid Lipid Nanoparticles
for to be unrivaled contrasted and those given orally or A Review”, International Journal of Applied Pharmaceutics, 5(2).
intramuscularly in the comparable measurement [56]. A 8-18. 2013.
few reports are accessible on the rectal medication organization [22] Antonio, J. and Eliana, S, Adv. Drug Delivery Rev, 59, 478-490.
through SLN in the writing [57]. Concentrated the fuse of 2007.
[23] Vyas, S, and Khar, R, “Controlled Drug Delivery - Concepts and
diazepam into SLN for rectal organization so as to give a Advances”, First Edition, Vallabh Prakashan 38-50. 2002.
fast activity. They concentrated that lipid network which [24] Joseph, R. and Vincent, H, “Controlled Drug Delivery -
is Solide at body temperature is not a gainful framework Fundamentals and Applications”, 2nd Edition, 4-33.
for diazepam rectal conveyance. They resolved to utilize [25] Omray, L., “Formulation and Characterization of Solid Lipid
lipids which dissolve around body temperature in their Nanoparticles for Transdermal Delivery of Testosterone”
International Journal Of Pharma Sciences And Research (Ijpsr), 5.
next tests. PEG covering is by all accounts a confident 323-328. 2014.
approach on rectal conveyance and thusly, improvement [26] Chaturvedi, S. and Kumar, V, “Production Techniques of Lipid
of bioavailability [58]. Nanoparticles: A Review”, Research Journal of Pharmaceutical,
Biological And Chemical Sciences, 3. 525-537. 2012.
[27] Schubert, M. and Muller-Goymann, C, “Solvent Injection as A
New Approach For Manufacturing Lipid Nanoparticles--
References Evaluation Of The Method and Process Parameters”, Eur J Pharm
Biopharm, 55. 125-131. 2003.
[1] Kamble, V., Jagdale, D. and Kadam, V., “Solid Lipid [28] Pragati, S., Kuldeep, S, and Satheesh, M, “Solid Lipid
Nanoparticles as Drug Delivery System”, International Journal of Nanoparticles A Promising Drug Delivery Technology”
Pharma and Bio Sciences, 1(3). 1-9. 2010. International Journal of Pharmaceutical Sciences and
[2] Sarangi, M. and Padhi, S, “Solid Lipid Nanoparticles A Review”, Nanotechnology, 2(2). 509-516. 2009.
Journal of Critical Reviews, 3 (3). 5-12. 2016. [29] Meyer, E. and Heinzelmann, H. “Scanning Force Microscopy.
[3] Hanumanaik, M., Patel, S. and Ramya Sree, K., “Solid Lipid Scanning Tunneling Microscopy II, Surface Science”, New York,
Nanoparticles A Review”, IJPSR, 4 (3). 928-940. 2013. Springer Verlag, 99-149.1992.
[4] Garud, A., Singh, D. and Garud, N, “Solid Lipid Nanoparticles [30] Drake, B., Prater, C., Weisenhorn, A., Gould S, Albrecht, T. and
Method, Characterization and Applications”, International Quate, C, “Imaging Crystals Polymers And Process In Water With
Current Pharmaceutical Journal, 1 (11). 384-393. 2012. The AFM”. Sci, 243. 1586-9. 1989.
[5] Kakadia, P. and Conway, B, “Solid Lipid Nanoparticles: A [31] Chen, H., Chang, X., Du, D., Liu, W., Liu, J., Weng, T. and
Potential Approach For Dermal Drug Delivery”, American Yang,Y, et al. “Podophyllotoxin-Loaded Solid Lipid
Journal Of Pharmacological Sciences. 2 (5). 1-7. 2014. Nanoparticles for Epidermal Targeting”, J. Control. Rel. 110. 296-
[6] Kamboj, S., Bala, S. and Nair, A., “Solid Lipid Nanoparticles An 306. 2006.
Effective Lipid Based Technology For Poorly Water Soluble [32] Heiati, H., Tawashi, R. and Phillips, N, “Solid Lipid Nanoparticles
Drugs”, International Journal Of Pharmaceutical Sciences Review As Drug Carriers - II. Plasma Stability And Bio-Distribution of
And Research, 5 (2). 78-90. 2010. Solid Lipid Noparticles Containing The Lipophilic Prodrug
[7] Swathi, G., Prasanthi, N., Manikiran, S. and Ramara, N, “Solid 3'azido-3'-Deoxythymidine Palmitate in Mice”, Int. J. Pharm,149.
Lipid Nanoparticles: Colloidal Carrier Systems For Drug 255-265. 1997.
Delivery”, Ijpsr, 1 (12). 01-16. 2010. [33] Cavalli, R., Caputo, O., Marengo, E., Pattarino, F. and Gasco M,
[8] Yadav, P., Soni, G., Mahor, A., Alok, S., Singh, P. and Verma, A. “The Effects of Components of Micro Emulsions on Both Size
“Solid Lipid Nanoparticles: An Effective and Promising Drug and Crystalline Structure of Solid Lipid Nanoparticles (SLN)
Delivery System- A Review”, Ijpsr, 5 (4). 1152-1162. 2014. Containing A Series of Model Molecules”, Pharmazie, 53.
[9] Wolfgang, M. and Karsten, M, “Adv. Drug. Deliv. Rev”, 47. 165- 392-396. 1998.
196. 2001. [34] Mühlen, A. and Mehnert, W. “Drug Release And Release
[10] Houli, L., Xiaobin, Z., Yukun, M. and Guangxi Z, “Solid Lipid Mechanism Of Prednisolone Loaded Solid Lipid Nanoparticles”,
Nanoparticles as Drug Delivery System”, J. Cont. Release, 133. Pharmazie, 53. 552. 1998.
238-244. 2009. [35] Eldem, T., Speiser, P. and Hincal, A, “Optimization Of Spray-
[11] Melike, U. Gulgun, Y, Int. J. Nanomedicine, 2(3). 289-300. 2007. Dried And Congealed Lipid Microparticles And Characterization
[12] Rupenagunta, A., Somasundaram, I., Ravichandiram, V., Kausalya, Of Their Surface Morphology By Scanning Electron Microscopy,
J. and Senthilnathan, B, “Solid Lipid Nanopar-Ticles- A Versatile Pharm Res, 8. 47-54. 1991.
Carrier System”, J Pharm Res, 4. 2069-2075. 2011. [36] Speiser, P, “Lipidnanopellets als Tragersystem Fur Arzneimittel
[13] Reddy, R. and Shariff, A., “Solid Lipid Nanoparticles An Zur Peroralem Anwendung”,European Patent No. EP 0167825.
Advanced Drug Delivery System”, Ijpsr, 4(1). 161-171. 2013. 1990.
[14] Ramteke, K., Joshi, S. and Dhole, S., “Solid Lipid Nanoparticle: A [37] Cavalli, R., Gasco, M., Chetoni, P., Burgalassi, S. and Saettone, M,
Review”, IOSR Journal Of Pharmacy, 2(6). 34-44. 2012. “Solid Lipid Nanoparticles as Ocular Delivery System for
Tobramycin”, Int. J. Pharm, 15. 241-5. 2002.
[15] Munireddy, M., Thakur, R., Patel, R. and Mamatha, M, “Solid
Lipid Nanoparticles an Effective Drug Delivery System”, [38] Greenberg, H., Shwayder, T., Bieszk, N. and Fivenson, D,
American Journal of Pharm Tech Research, 2(3). 2012. “Clotrimazole Betamethasone Dipropionate: A Review Of Costs
And Complications In The Treatment Of Common Cutaneous
[16] Khan, S “Solid Lipid Nanoparticles A Review”, World Journal Of
Fungal Infections”, Pediatric Dermatology, 19. 78-81. 2002.
Pharmacy And Pharmaceutical Sciences, 96-115. 2012.
[17] Ekambaram, P., Sathali, A. and Priyanka, K, “Solid Lipid
[39] Souto, E. and Müller, R, “The Use of SLN and NLC As Topical
Particulate Carriers For Imidazole Antifungal Agents”, Pharmazie,
Nanoparticles and Lipid Nanostructures Overview”, Scientific
61. 431-437. 2006.
Review &Chemical Communication, 2. 216-220. 2011.
[18] Rawat, A., Jain, M. and Singh, A, “Studies on Binary Lipid Matrix
[40] Ekambaram, P., Sathali, A. and Priyanka, K, “Solid Lipid
Nanoparticles A Review”, Sci. Revs. Chem. Commun, 2(1),
Based Solid Lipidnanoparticles of Repaglinide”, In Vitro And
80-102. 2012.
In Vivo Evaluation, Journal Of Pharmaceutical Sciences. 2.
66-78. 2011. [41] Machlin, L, “Vitamin E A Comprehensive Treatise” New York
And Basel: Marcel Dekker 1980.
[19] Sinharanjan, V., Srivastava, S, Honey, G. and Jindal, V, “Solid
Lipid Nanoparticles Trends and Implications In Drug Targeting”, [42] Garud, A., Singh, D. and Garud, N, “Solid Lipid Nanoparticles
International Journal of Advances In Pharmaceutical Sciences, 2. Method, Characterization and Applications”, International
212-238. 2010. Current Pharmaceutical Journal, 1. 384-393. 2012.
 Nanoscience and Nanotechnology Research 72

[43] Schubert, M. and Goymann, C “Solvent Injection as A New Pharmaceutical Actives”, Drug Delivery Technology, 9 (8). 2009.
Approach for Manufacturing Lipid Nanoparticles– Evaluation of [51] Muèller, R., Maèder, K. And Sven Gohla, “Solid Lipid
The Method and Process Parameters”, Eur J Pharm Biopharm, Nanoparticles for Controlled Drug Delivery A Review 0f The
55(1). 125-131. 2003. State of The Art”, European Journal 0f Pharmaceutics And
[44] Makai, M., Sanyi, E., Ekany, I. and Nemeth, I. “Structural Biopharmaceutics, 50. 161-177. 2000.
Properties of Non-Ionic Surfactant, Glycerol, Paraffin Lyotropic [52] Pinto, J. and Muèller, R, “Pellets As Carriers 0f Solid Lipid
Crystals”, Colloid Polym Sci, 281. 839-844. 2003. Nanoparticles for Oral Administration 0f Drugs”, Die Pharmazie,
[45] Goymann, C., Swarbrick, J. and Boylan, J, “Liquid Crystals in 506-509. 1999.
Drug Delivery. In Eds. Encyclopedia of Pharmaceutical [53] MuèLler, R., Luèck, J., and Fuè, R, “GewebsspeziSche
Technology”, New York and Basel: Marcel Dekker, 834-853. 2002. Arzneistoffapplikation”, German Patent Application No.197 45
[46] Verma, V, And Ram, A, “Preparation Characterization and 950. 1. 1997.
In-Vitro Release of Piroxicam-Loaded Solid Lipid Nanoparticles”, [54] Bhaskar, K., Anbu, J. Ravichandiran, V. and Venkateswarlu, Y,
International Journal of Pharmaceutical Sciences and “Lipid Nanoparticles For Transdermal Delivery of Flurbiprofen
Nanotechnology, 3(3). 1136-1146. 2010. Formulation, In Vitro, Ex Vivo and In Vivo Studies”, Lipids In
[47] Kaur, I., Bhandari, R., Bhandari ,S. and Kakkar, V, “Potential of Health and Disease, 8(6). 2009.
Solid Lipid Nanoparticles In Brain Targeting” J Control Release, [55] Ekambaram, P., Sathali, A. and Priyanka, K, “Solid Lipid
127. 97-109. 2008. Nanoparticles: A Review”, Scientific Reviews and Chemical.
[48] Kumar, R. and Katare, O, “Lecithin Organogels as A Potential Communication, 2(1). 80-102. 2012.
Phospholipid Structured System For Topical Drug Delivery: A [56] Sznitowska, M., Gajewska, M. and Janicki, S., Eur J
Review”, AAPS. Pharmscitech, 6E298-E310. 2005. Pharmbiopharm, 52. 159-63. 2001.
[49] YChien, Y., Keshary, P., Hung, Y, and Sarpotdar, P, [57] Sznitowska, M., Janicki, S. and Gajewska, M, Acta Polonpharm,
“Comparative Controlled Skin Permeation of Nitroglycerin From 57.61-4.2000.
Marketed Transdermal Delivery Systems”, J Pharm Sci, 72. [58] Sanap, G. And Mohanta, G, “A Review Solid Lipid Nanoparticle
968-970. 1983. A Potential Drug Delivery Carrier”, International Journal of
[50] Loxley, A, “Solid Lipid Nanoparticles for The Delivery of Chemical and Pharmaceutical Analysis, (2). 52-62.2014.